[Remote] Director, Trade & Distribution at Dyno Therapeutics

Waltham, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Neuromuscular DiseaseIndustries

Requirements

Extensive market access experience
Experience leading successful product launches
Experience driving revenue growth
Strong reputation for excellent cross-functional collaboration
Strategic thinker
Commercial leader

Responsibilities

Develop, lead, and implement the strategy of the trade and distribution approach
Partner with the payer team to ensure the distribution channel strategy meets the needs and expectations of the payer community and sites of care
Execute strategy and operationalize 3PL, wholesalers/specialty distributors, and specialty pharmacies to ensure availability and support for Dyne products
Collaborate with legal, finance and other internal operations functions to draft, execute, and implement compliant contracts with key trade and distribution partners
Monitor services agreements to ensure compliance and hold partners accountable to agreements
Partner with Patient Support, Marketing, Commercial Analytics and Sales to continually monitor, assess and evolve the distribution strategy and tactics
Identify, develop, and execute on practical compliance/adherence and other patient support programs that use distribution and trade partners
Lead and manage channel engagement with all stakeholders associated with 3PL, Specialty Distribution, and Specialty Pharmacy/Specialty Infusion Providers
Work with channel partners to ensure proper purchasing, stocking, and inventory

Skills

Market Access

Distribution Strategy

Channel Strategy

Contract Management

Supply Chain

Commercialization

Launch Readiness

Cross-functional Collaboration

Revenue Growth

Dyno Therapeutics

Develops AI-optimized gene therapy vectors

About Dyno Therapeutics

Dyno Therapeutics focuses on advancing gene therapy by utilizing Artificial Intelligence to create Adeno-associated virus (AAV) vectors. These vectors are essential tools for delivering genetic material into cells, which is crucial for effective gene therapy. The company's AI technology enables the design and optimization of these vectors, potentially enhancing the success of gene therapies. Dyno collaborates with major pharmaceutical and biotech companies, such as Astellas, Roche, Sarepta, and Novartis, to develop therapies for various diseases affecting the skeletal and cardiac muscles, central nervous system, liver, and eyes. Unlike many competitors, Dyno's unique approach leverages AI to improve the performance of AAV vectors, setting it apart in the biotech field. The company's goal is to improve gene therapy outcomes through its advanced vector technology, ultimately benefiting patients with serious health conditions.

Watertown, MassachusettsHeadquarters

2018Year Founded

$106MTotal Funding

SERIES_ACompany Stage

AI & Machine Learning, Biotechnology, HealthcareIndustries

51-200Employees

Benefits

Remote Work Options

Risks

Gene therapy investment slowdown may impact Dyno's growth and innovation.

Manufacturing bottlenecks could hinder scaling of Dyno's operations.

Increased competition from companies like Form Bio challenges Dyno's market position.

Differentiation

Dyno uses AI to design optimized AAV vectors for gene therapy.

Their AI-driven CapsidMap platform enhances AAV vector development for muscle gene therapies.

Partnerships with major pharma companies like Astellas and Roche boost Dyno's market presence.

Upsides

AI-driven capsid design improves delivery efficiency and reduces manufacturing costs.

Collaboration with NVIDIA enhances biological sequence design for gene therapies.

Generative AI increases efficiency of eye and brain-targeted capsid delivery significantly.

Land your dream remote job 3x faster with AI

Try Jobo Free